Johnson & Johnson said on Wednesday it had found a
problem with a batch of the drug substance for its COVID-19 vaccine being
produced by Emergent Biosolutions, and said the batch did not advance to the
final fill-and-finish stage.
اضافة اعلان
J&J did not say how many vaccine doses the batch would
have produced. The New York Times reported that about 15 million doses were
ruined, without citing a source.
The Times said that workers had conflated ingredients for
the J&J vaccine and a coronavirus vaccine developed by AstraZeneca Plc,
which is produced at the same plant, several weeks ago.
The manufacturing misstep follows manufacturing issues at
J&J, which is seen as one of the most important COVID-19 vaccines globally,
because its vaccine is a single dose and requires relatively little special
handling. J&J said manufacturing was on track.
J&J did not directly respond to a question about the
number of doses ruined, only responding with a statement saying that the batch
being produced at Emergent Biosolutions' site in Baltimore did not meet quality
standards and did not advance to the fill-and-finish stage, which is handled by
another company.
J&J said the problem at the Emergent Biosolutions plant,
which is not yet authorized to produce the drug substance for the vaccine, was
identified and addressed with Emergent and shared with the US Food and Drug
Administration.
J&J said it was sending more people to supervise
manufacturing at the plant.
News of the setback comes at a time when the Biden
administration has been trying to accelerate shipments of COVID-19 vaccines to
US states.
Last month, the Biden administration said it was exploring
ways to increase manufacturing of J&J's vaccine, as the expected levels of
early doses were less than it hoped at the time.
J&J said it has met its commitment to deliver more than
20 million doses of its single-shot vaccine by the end of March in the United
States.
In addition to contracting with Emergent Biosolutions to
produce the vaccine drug substance, J&J tapped Catalent Inc to handle the
final stage - called fill and finish.
Johnson & Johnson faced some manufacturing issues
earlier in the year.
A European Union official in early March told Reuters that
Johnson & Johnson told the bloc it was facing supply issues that might
complicate plans to deliver 55 million doses of its COVID-19 vaccine in the
second quarter of the year.
Emergent, which is a manufacturing partner to both J&J
and AstraZeneca, referred to J&J's statement when contacted for comment.
Astrazeneca, whose vaccine is not yet authorized in the US,
said: "We are aware of the reports regarding the facility and we
understand Emergent is investigating the matter."
.jpg)
.jpg)
